U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks of a painful complication and deaths.

A man and woman, both with sickle cell, share what their experience was like finding love, and what prospective partners need to know.

Sickle cell disease (SCD) is a group of painful and life-threatening genetic disorders that affect hemoglobin, the major protein that carries oxygen in red blood cells. It occurs in nearly 100,000 people in the United States and millions worldwide.

Pfizer is pulling its sickle cell disease (SCD) treatment voxelotor (Oxbryta) from global markets after data review showed an imbalance in deaths among patients taking the drug. "The overall benefit of the drug no longer outweighs the risk in the approved sickle cell patient population,

Pfizer is withdrawing all of its sickle cell disease drug, Oxbryta, worldwide because of safety concerns. Pfizer ( PFE) shares declined Thursday after the drug maker recalled all lots of its sickle cell disease medicine worldwide because of concerns it could lead to severe pain and possibly death in patients.

September is National Sickle Cell Awareness Month. It’s a time used to raise awareness about the disease. WMAR-2 News spoke to a family in Baltimore directly impacted by the disease.

As a Black woman who serves as MDwise’s Equity Officer, Anye Carson is aware of sickle cell disease (SCD). She knows that it predominantly affects Black people, can cause debilitating […]

The decision is based on the totality of clinical data, which now indicates that the benefit of Oxbryta no longer outweighs the risks associated with its use, Pfizer said. Pfizer said it will further review and investigate the available data and had notified regulatory authorities about its findings.

European regulators suspended the approval of Pfizer Inc.’s sickle cell anemia drug, Oxbryta, citing a higher rate of disease complications in patients who started taking the drug.